The latest $1 trillion chipmaker now costs about 40 times its expected 2027 earnings. Its bigger, faster-growing competitor costs about 15 times its own.
Everpure (NYSE:P) outlined a strategy centered on expanding its enterprise storage business while pursuing new opportunities in AI infrastructure, data software and hyperscale deployments, with executives projecting accelerated growth and higher profitability through fiscal 2028.
At the company’s i
Can Boeing turn its aerospace strengths into a durable recovery? Motley Fool analysts weigh its leadership, debt, and execution risks as they debate the stock's long-term potential.
Stitch Fix (NASDAQ:SFIX) reported fiscal 2026 revenue growth and improved profitability, while executives said a more challenging consumer environment, higher client acquisition costs and temporary first-quarter issues are expected to weigh on fiscal 2027 results.
For fiscal 2026, revenue rose 6.4%
Qualcomm (NASDAQ:QCOM) used the second day of its Snapdragon Summit to outline its vision for “personal AI,” highlighting new on-device AI software, wearable reference designs, audio platforms and partnerships intended to support agentic experiences across phones, PCs, cars, glasses and other connec
NeoVolta (NASDAQ:NEOV) said fiscal 2026 marked a strategic shift from a primarily residential battery-storage provider toward a broader energy-storage platform spanning residential, commercial and industrial, and utility-scale markets, though the company reported a sharp fourth-quarter revenue decli
One platform is generating record cash flow and closing thousands of AI deals across the enterprise. The other just reached consistent profitability after years of losses and is still earning back investor confidence.
There's been plenty of bad news to digest for Lucid investors, but its recent partnership with Bolt in Europe is at least positive -- even if mostly hype for now.
GSK (NYSE:GSK) is advancing a respiratory and immunology pipeline centered on longer-acting biologics, more targeted patient selection and combination approaches, according to Kaivan Khavandi, the company’s senior vice president and global head of Translational and Development Sciences.
Speaking at
XLV's broader diversification and lower fees appeal to cost-conscious investors, while PJP's concentrated pharma bet has outperformed over the past year.
Beyond Menu provides exceptional support by addressing the specific needs of diners and restaurant owners, providing easy access and fast issue resolution
Arm's royalty model compounds reliably across billions of devices. TSMC's factories build the chips that power every major AI system in the world. Both are essential, but only one is truly irreplaceable.
